Drug intelligence / Profile preview

RH127

Development stage: Preclinical
Lead developer: Shenzhen Rhegen Biotechnology
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics

Overview

RH127 is a preclinical **mRNA combination vaccine** being developed by Shenzhen Rhegen Biotechnology for prevention of infections caused by respiratory syncytial virus and human metapneumovirus. The vaccine is designed to encode antigens from both respiratory viruses and elicit protective antiviral immune responses against RSV and hMPV.

Other names: Pan-respiratory Combination Vaccine泛呼吸道联苗

Targets

hMPV (Human metapneumovirus)

Beyond the preview

Go deeper on RH127.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RH127.

Explore the full profile